About Ocugen
Ocugen is a company based in Aurora (United States) founded in 2013. The company has 95 employees as of December 31, 2024. Ocugen offers products and services including Gene Therapies, Vaccines, and Cell Therapies. Ocugen operates in a competitive market with competitors including Adaptive Biotechnologies, Moderna, Kriya Therapeutics, Annexon and Generate Biomedicines, among others.
- Headquarter Aurora, United States
- Employees 95 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Ocugen, Inc.
-
Annual Revenue
$4.05 M (USD)-32.82as on Dec 31, 2024
-
Net Profit
-$54.05 M (USD)14.31as on Dec 31, 2024
-
EBITDA
-$52.79 M (USD)18.57as on Dec 31, 2024
-
Latest Funding Round
$14.28 M (USD), Post-IPO
May 07, 2020
- Investors
-
Employee Count
95
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Ocugen
Ocugen is a publicly listed company on the NASDAQ with ticker symbol OCGN in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Ocugen
Ocugen offers a comprehensive portfolio of products and services, including Gene Therapies, Vaccines, and Cell Therapies.
Treats inherited retinal diseases like retinitis pigmentosa
Develops mucosal vaccines for infectious diseases
Addresses orthopedic diseases through regenerative approaches
People of Ocugen
Unlock access to complete
Unlock access to complete
Funding Insights of Ocugen
Investors in Ocugen
Ocugen has secured backing from 6 investors, including institutional and angel investors. Prominent investors backing the company include Colorado Office of Economic Development and International Trade, Lancaster Group and Abdi Ibrahim.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Provides financial advisory services, including planning, analysis, and wealth management.
|
Locked | Locked | Locked | |
|
Economic development and international trade are facilitated for Colorado businesses.
|
Locked | Locked | Locked | |
|
AI
Abdi Ibrahim |
-
|
Locked | Locked | Locked |
Investor details for Ocugen
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Ocugen
Investment portfolio details for Ocugen
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Ocugen
Detailed financials for Ocugen
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Ocugen Comparisons
Peer comparison for Ocugen
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Ocugen
Ocugen operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Adaptive Biotechnologies, Moderna, Kriya Therapeutics, Annexon and Generate Biomedicines, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Clinical diagnostics and drug discovery for immune diseases are provided.
|
|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Developer of therapeutic solutions for the treatment of diabetes
|
|
| Locked | Locked | Locked |
Developer of antibodies to treat complement-mediated neurodegenerative diseases
|
|
| Locked | Locked | Locked |
Developer of novel protein-based therapeutics using machine learning and biological engineering
|
|
| Locked | Locked | Locked |
Developer of immunotherapies for the treatment of infectious diseases and cancer
|
Detailed competitors of Ocugen
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Ocugen
Complete news archive for Ocugen
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Ocugen
Ocugen was founded in 2013 and raised its 1st funding round 2 years after it was founded.
Ocugen is headquartered in Aurora, United States. It is registered at Aurora, Colorado, United States.
As of Dec 31, 2024, the latest employee count at Ocugen is 95.
Annual revenue of Ocugen is $4.05M as on Dec 31, 2024.
Founded in 2013 and based in Aurora, United States, Ocugen operates in the biotechnology sector, focusing on protein therapeutics for eye diseases. Treatments are advanced for conditions such as ocular graft versus host disease, retinitis pigmentosa, geographic atrophy, wet age-related macular degeneration, and diabetic retinopathy. Key products include OCU400 for retinal degeneration, OCU410 for dry age-related macular degeneration, and OCU200 for diabetic macular edema and retinopathy.
Ocugen's top competitors include Moderna, Adaptive Biotechnologies and Annexon.
Ocugen offers Gene Therapies, Vaccines, and Cell Therapies.
Yes, Ocugen is publicly traded on NASDAQ under the ticker symbol OCGN.
Ocugen has 6 investors. Key investors include Colorado Office of Economic Development and International Trade, Lancaster Group, Abdi Ibrahim, Frank Leo, and John Zhang.
The ticker symbol of Ocugen is OCGN on NASDAQ.